What is the point of guidelines? Benzodiazepine and z-hypnotic use by an elderly population

Sleep Medicine

Volumn 13, Issue 7, 2012, Pages 893-897

  Neutel, C Ineke ^a   Skurtveit, Svetlana ^b,c   Berg, Christian ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Benzodiazepines; Elderly; Guidelines; Inappropriate medication; Insomnia; Sleep medication; Z Hypnotics

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE; HYPNOTIC AGENT; OXAZEPAM; ZOPICLONE;

AGE; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; DRUG DOSE REGIMEN; DRUG USE; ELDERLY CARE; FEMALE; HUMAN; MALE; NORWAY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEX DIFFERENCE; SLEEP MEDICINE; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPNOTICS AND SEDATIVES; INAPPROPRIATE PRESCRIBING; MALE; NORWAY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; SEX FACTORS;

EID: 84863860044     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2011.12.014     Document Type: Article

References (51)

1. Rognstad S., Brekke M., Fetveit A., Spigset O., Wyller T.B., Straand J. The Norwegian General Practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients. A modified Delphi study. Scand J Prim Health Care 2009, 27(3):153-159.
2. Fick D.M., Cooper J.W., Wade W.E., Waller J.L., Maclean J.R., Beers M.H. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003, 163(22):2716-2724.
3. Gallagher P., Ryan C., Byrne S., Kennedy J., O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther 2008, 46(2):72-83.
4. Ashton CH. The Ashton Manual. Benzodiazepines: how they work and how to withdraw,; 2002.. http://www.benzo.org.uk/manual/.
5. Ashton H. Guidelines for the rational use of benzodiazepines. When and what to use. Drugs. 1994, 48(1):25-40.
6. Beers M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997, 157(14):1531-1536.
7. CPA The Compendium of Pharmaceuticals and Specialties (CPS) 2009, CPhA, Ottawa.
8. Nelson J., Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol 1999, 6(2):69-83.
9. Glass J., Lanctot K.L., Herrmann N., Sproule B.A., Busto U.E. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005, 331(7526):1169.
10. Johnell K., Fastbom J. The use of benzodiazpines and related drugs amongst older people in Sweden: associated factors and concomitant use of other psychotropics. Int J Geriatr Psychiatry 2009, 24(7):731-738.
11. Petitjean S., Ladewig D., Meier C.R., Amrein R., Wiesbeck G.A. Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. Int Clin Psychopharmacol 2007, 22(5):292-298.
12. Neutel C.I. The epidemiology of long-term benzodiazepine use. Int Rev Psychiatry 2005, 17(3):189-197. [Review].
13. Isacson D. Long-term benzodiazepine use: factors of importance and the development of individual use patterns over time - a 13-year follow-up in a Swedish community. Soc Sci Med 1997, 44(12):1871-1880.
14. Barnas C., Fleischhacker W.W., Whitworth A.B., Schett P., Stuppack C., Hinterhuber H. Characteristics of benzodiazepine long-term users: investigation of benzodiazepine consumers among pharmacy customers. Psychopharmacology (Berl) 1991, 103(2):233-239.
15. Ishigooka J., Sugiyama T., Suzuki M., Kobayashi K., Takeuchi H., Murasaki M. Survival analytic approach to long-term prescription of benzodiazepine hypnotics. Psychiatry Clin Neurosci 1998, 52(5):541-545. [Research Support, Non-U.S. Gov't.].
16. Berg C S.S., Handal M., Skurtveit S. Z-hypnotics - the dominating hypnotics in Norway. Norsk Farmaceutisk Tidsskrift 2011, 4:20-23.
17. Holbrook A.M., Crowther R., Lotter A., Cheng C., King D. The diagnosis and management of insomnia in clinical practice. a practical evidence-based approach. CMAJ 2000, 162(2):216-220.
18. Lenze E.J., Pollock B.G., Shear M.K., Mulsant B.H., Bharucha A., Reynolds C.F., et al. Treatment considerations for anxiety in the elderly. CNS Spectr 2003, 8(12 Suppl. 3):6-13. [Research Support, U.S. Gov't., P.H.S. Review].
19. Lader M. Rebound insomnia and newer hypnotics. Psychopharmacology (Berl) 1992, 108(3):248-255.
20. Rickels K., Schweizer E., Case W.G., Greenblatt D.J. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990, 47(10):899-907.
21. Neutel C.I. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 1995, 5(3):239-244.
22. Neutel C.I., Maxwell C.J. The benzodiazepine treadmill - does one prescription lead to more?. Pharmacoepidemiol Drug Saf 1996, 5(1):39-42.
23. Neutel C.I., Perry S., Maxwell C. Medication use and risk of falls. Pharmacoepidemiol Drug Saf 2002, 11(2):97-104.
24. Kallin K., Jensen J., Olsson L.L., Nyberg L., Gustafson Y. Why the elderly fall in residential care facilities, and suggested remedies. J Fam Pract 2004, 53(1):41-52. [Research Support, Non-U.S. Gov't.].
25. Paterniti S., Dufouil C., Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol 2002, 22(3):285-293.
26. WHO. Collaborating Centre for Drugs Statistics Methodology. Oslo, Norway, www.Whocc.no; 2010 [accessed 02/01/2012].
27. Furu K., Wettermark B., Andersen M., Martikainen J.E., Almarsdottir A.B., Sorensen H.T. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010, 106(2):86-94.
28. Furu K. Drug utilisation in a public health perspective: establishing a national prescription register in Norway. Norw J Epidemiol 2001, 11:55-60.
29. McNutt L.A., Coles F.B., McAuliffe T., Baird S., Morse D.L., Strogatz D.S., et al. Impact of regulation on benzodiazepine prescribing to a low income elderly population, New York State. J Clin Epidemiol 1994, 47(6):613-625.
30. Weintraub M., Singh S., Byrne L., Maharaj K., Guttmacher L. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA 1991, 266(17):2392-2397.
31. Ross-Degnan D., Simoni-Wastila L., Brown J.S., Gao X., Mah C., Cosler L.E., et al. A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population. Int J Psychiatry Med 2004, 34(2):103-123.
32. Simoni-Wastila L., Ross-Degnan D., Mah C., Gao X., Brown J., Cosler L.E., et al. A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in medicaid patients with chronic psychiatric and neurologic disorders. Clin Ther 2004, 26(2):322-336.
33. Bliwise D.L. The pit (of sleeplessness) and the pendulum (of regulation). Sleep Med 2010, 11(1):7-8.
34. O'Mahony D., Gallagher P.F. Inappropriate prescribing in the older population: need for new criteria. Age Ageing 2008, 37(2):138-141.
35. Barnett K., McCowan C., Evans J.M., Gillespie N.D., Davey P.G., Fahey T. Prevalence and outcomes of use of potentially inappropriate medicines in older people: cohort study stratified by residence in nursing home or in the community. Qual Saf Health Care 2011.
36. Holbrook A., Goldsmith C. Placebos: our most effective therapy?. Can J Clin Pharmacol 2004, 11(1):e39-e40.
37. Leipzig R.M., Cumming R.G., Tinetti M.E. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999, 47(1):30-39.
38. Berdot S., Bertrand M., Dartigues J.F., Fourrier A., Tavernier B., Ritchie K., et al. Inappropriate medication use and risk of falls - a prospective study in a large community-dwelling elderly cohort. BMC Geriatr 2009, 9:30.
39. Fu A.Z., Liu G.G., Christensen D.B. Inappropriate medication use and health outcomes in the elderly. J Am Geriatr Soc 2004, 52(11):1934-1939. [Research Support, U.S. Gov't., P.H.S.].
40. Neutel C.I., Hirdes J.P., Maxwell C.J., Patten S.B. New evidence on benzodiazepine use and falls: the time factor. Age Ageing 1996, 25(4):273-278.
41. Maxwell C.J., Neutel C.I., Hirdes J.P. A prospective study of falls after benzodiazepine use: a comparison of new and repeat use. Pharmacoepidemiol Drug Saf 1997, 6(1):27-35.
42. Bartlett G., Abrahamowicz M., Grad R., Sylvestre M.P., Tamblyn R. Association between risk factors for injurious falls and new benzodiazepine prescribing in elderly persons. BMC Fam Pract 2009, 10:1.
43. Pariente A., Dartigues J.F., Benichou J., Letenneur L., Moore N., Fourrier-Reglat A. Benzodiazepines and injurious falls in community dwelling elders. Drugs Aging 2008, 25(1):61-70.
44. Breslow N.E., Day N.E. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ 1980, (32):5-338.
45. Neutel C.I., Morrison H. Could recent decreases in breast cancer incidence really be due to lower HRT use? Trends in attributable risk for modifiable breast cancer risk factors in Canadian women. Can J Public Health 2010, 101(5):405-409.
46. Wagner A.K., Ross-Degnan D., Gurwitz J.H., Zhang F., Gilden D.B., Cosler L., et al. Effect of New York State regulatory action on benzodiazepine prescribing and hip fracture rates. Ann Intern Med 2007, 146(2):96-103.
47. Lesser G.T. Benzodiazepines and hip fractures. Ann Intern Med 2007, 147(5):347-348. [author reply 8].
48. Wagner A.K., Soumerai S.B., Zhang F., Mah C., Simoni-Wastila L., Cosler L., et al. Effects of state surveillance on new post-hospitalization benzodiazepine use. Int J Qual Health Care 2003, 15(5):423-431.
49. Lagnaoui R., Tournier M., Moride Y., Wolfson C., Ducruet T., Begaud B., et al. The risk of cognitive impairment in older community-dwelling women after benzodiazepine use. Age Ageing 2009, 38(2):226-228.
50. Pat McAndrews M., Weiss R.T., Sandor P., Taylor A., Carlen P.L., Shapiro C.M. Cognitive effects of long-term benzodiazepine use in older adults. Hum Psychopharmacol 2003, 18(1):51-57.
51. Verdoux H., Lagnaoui R., Begaud B. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med 2005, 35(3):307-315.